Insider · CIK 0001523522
Kirk G. Nielsen
Files at CVRX (CVRx, Inc.), SGP (SpyGlass Pharma, Inc.). First filing May 14, 2025, latest Feb 10, 2026.
In brief
Kirk G. Nielsen files SEC Form 4 as director and 10% owner at CVRX (CVRx, Inc.), and also at SGP (SpyGlass Pharma, Inc.). Since May 14, 2025, Kirk G. Nielsen has reported 3 open-market buys worth $3.7M and 0 open-market sells worth $0, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Kirk G. Nielsen has 0, so none is measured yet.
The newest scored trade: bought $2.6M of SGP on Feb 9, 2026, filed Feb 10, 2026, scored 58 (moderate). In the last 12 months: 1 buy worth $2.6M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
CVRX: CVRx, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SGP: SpyGlass Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | SpyGlass Pharma, Inc. | $2.6M 165,000 shares | +5% | - | |
| 45Moderate | CVRx, Inc. | $60k 10,966 shares | +1% | +30% from low-66% from high | |
| 76Notable | CVRx, Inc. | $977k 187,813 shares | +11% | 0% from low-74% from high |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | CVRX CVRx, Inc. | AGrant or award Common Stock | +8,720 | $0.00 | $0 | 8,720 | Jun 3, 2026 |
| Jun 1, 2026 | CVRX CVRx, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,182 | $0.00 | $0 | 11,182 | Jun 3, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnote | -1,690,230 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See footnote | -548,067 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-2 Preferred Stockderivativeindirect: See Footnote | -548,067 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -359,255 | - | - | 0 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +1,690,230 | - | - | 1,690,230 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Footnote | +548,067 | - | - | 2,238,297 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Footnote | +548,067 | - | - | 2,786,364 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See Footnote | +359,255 | - | - | 3,145,619 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +165,000 | $16.00 | $2.6M | 3,310,619 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnote | -9,689,922 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -3,142,015 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-2 Preferred Stockderivativeindirect: See Footnote | -3,142,015 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -2,059,573 | - | - | 0 | Feb 10, 2026 |
| Feb 5, 2026 | SGP SpyGlass Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,400 | $0.00 | $0 | 27,400 | Feb 9, 2026 |
| Jun 3, 2025 | CVRX CVRx, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,554 | $0.00 | $0 | 19,554 | Jun 5, 2025 |
| May 15, 2025 | CVRX CVRx, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +10,966 | $5.45 | $60k | 1,910,134 | May 19, 2025 |
| May 12, 2025 | CVRX CVRx, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +25,200 | $4.79 | $121k | 1,736,555 | May 14, 2025 |
| May 13, 2025 | CVRX CVRx, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +101,413 | $5.29 | $536k | 1,837,968 | May 14, 2025 |
| May 14, 2025 | CVRX CVRx, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +61,200 | $5.23 | $320k | 1,899,168 | May 14, 2025 |
Questions about Kirk G. Nielsen
Answered from the filings on this page, as of the latest one.
Is Kirk G. Nielsen buying or selling?
In the last 12 months Kirk G. Nielsen reported 1 open-market buy worth $2.6M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.6M of SGP on Feb 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Kirk G. Nielsen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kirk G. Nielsen has 0.
Where does Kirk G. Nielsen file Form 4?
Kirk G. Nielsen has filed Form 4 at CVRX (CVRx, Inc.); SGP (SpyGlass Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.